This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Efficacy and Safety of Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) and Insulin Glargine and Lixisenatide (IGlarLixi) in Patients with Type 2 Diabetes

Efficacy and Safety of Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) and Insulin Glargine and Lixisenatide (IGlarLixi) in Patients with Type 2 Diabetes

Format

Webcast

Time to Complete

1.50 hours

Released

November 29, 2017

Expires

November 29, 2018
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM
1.50 / ANCC Contact Hours

Accredited Provider

Jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System, Amedco, and MedNet

Commercial Supporters

Supported by Novo Nordisk

Program Description

This webcast is intended to improve care of patients with type 2 diabetes (T2D) by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of diabetologists, endocrinologists, internal medicine physicians, family medicine physicians, physician assistants, nurse practitioners, registered nurses, and allied healthcare professionals involved in the diagnosis and treatment of patients with T2D.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Identify treatment intensification options with fixed ratio combination of IDegLira in achieving glycemic control, blood glucose target ranges, and weight loss in patients with T2D
  • Select treatment intensification options with fixed ratio combination of IGlarLixi in achieving glycemic control, blood glucose target ranges, and weight loss in patients with T2D

Conflict Of Interest Disclosure Policy

It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & Health, Dallas and Amedco, St. Paul, MN to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.

Faculty

Bruce W. Bode, MD
Atlanta Diabetes Associates
Associate Professor of Medicine
Emory University School of Medicine
Atlanta, GA

Dr. Bode discloses he is a Consultant for Novo Nordisk, Sanofi, Boehringer-Ingelheim/Lilly USA, LLC, and Janssen; is on the Speaker’s Bureaus of Novo Nordisk, Sanofi, Boehringer-Ingelheim/Lilly USA, LLC, Janssen, and AstraZeneca; and received Grant Support from Novo Nordisk, Sanofi, Boehringer-Ingelheim/Lilly USA, LLC, and Janssen.

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Bruce W. Bode, MD, listed his disclosures under the Faculty heading above.

Kamatham A. Naidu, PhD (MedNet, LLC), has no relevant financial relationships to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and MedNet. The A. Webb Roberts Center for CME of Baylor Scott & Health by the ACCME to provide continuing medical education for physicians.

Designation Statement

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.50

Type

CE for Nurses

Accreditation Statement

Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and MedNet, LLC.

Designation Statement

Maximum of 1.50 contact hours.

Disclosure of Unlabeled Use

It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & Health, Dallas and Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

NON-ENDORSEMENT OF PRODUCTS
Amedco does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating in or receiving credit for this webcast. During the period November 28, 2017 through November 28, 2018, participants must read all of the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or above on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME Provider at 214-820-2317.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

Webb Roberts Center for CME of Baylor Scott & Health and Amedco observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue